Randal J. Kirk Net Worth

Randal J. Kirk has an estimated net worth of $2.4 billion, according to Forbes Real-Time Billionaires, Randal J. Kirk profile (figures as of October 20, 2026). That is down from a peak of $2.6 billion.

Randal J. Kirk is an American businessman and investor known for pharmaceuticals and biotechnology. He started out as a practicing attorney, then moved into building and backing drug and life sciences companies. He founded Third Security in 1999 and later led Intrexon, which became Precigen in 2020. Along the way, he also held board roles with companies such as Scios and became known for a series of biotech deals and investments.

His wealth came from entrepreneurship, company sales, and long-running biotech investments. Kirk’s first business success was an injectable drug and vaccine distributor that he later sold. He then founded New River Pharmaceuticals, took it public in 2004, and sold it to Shire in 2007. He also became a major shareholder and chairman of Clinical Data before its sale in 2011. Forbes put his net worth at $2.4 billion in October 2026.

How Randal J. Kirk built his fortune

Kirk began his career in law and ran a practice until 1990. In 1983, he partnered with pharmacist John Gregory to launch General Injectables and Vaccines, a next-day pharmaceutical distributor. That company gave him his first entrepreneurial win and helped fund his shift into larger healthcare bets. After that, he spent much of his career starting, backing, and leading companies tied to drugs, biotech, and life sciences.

A big turning point came with New River Pharmaceuticals, which Kirk founded in 1996. He served as chairman and CEO, took the company public in 2004, and sold it to Shire in 2007. He later built Third Security into a life sciences investment firm and took on leadership roles at Intrexon, later renamed Precigen. His investments also included products such as nonbrowning apples and genetically modified salmon.

Forbes estimate and the money behind it

Forbes said Kirk was worth $2.4 billion on its real-time billionaires tracker as of October 20, 2026. That estimate fits the way he made his money: not from one salary, but from ownership stakes, company sales, and a long run in biotech investing. He is self-made, and his wealth has been tied to pharmaceuticals, healthcare, and businesses connected to Third Security and Precigen.

Even after changes at his companies, Kirk kept a central role in the business side of his portfolio. In 2020, he stepped down as CEO of Precigen and became executive chairman. That same year, Third Security liquidated its life sciences-focused VC funds, but it continued managing his family money. Those moves show how his fortune has stayed linked to private investing, public biotech holdings, and years of dealmaking.